A network pharmacological-based study of the mechanism of Liuwei Dihuang pill in the treatment of chronic kidney disease

Author:

Xie Xi1ORCID,Lou Hongjun2,Shi Ye3,Gan Guang3,Deng Hanqing4,Ma Xinwei1,Meng Mingfang1,Gao Xi2ORCID

Affiliation:

1. The First Clinical Medical College of Heilongjiang University of Traditional Chinese Medicine, Harbin, China

2. The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, China

3. College of Integrated Chinese and Western Medicine, Hunan University of Traditional Chinese Medicine, Changsha, China

4. The First Clinical Medical College of Hunan University of Traditional Chinese Medicine, Changsha, China.

Abstract

Background: Chronic kidney disease (CKD) is a progressive disease that poses a huge economic burden to society. Liuwei Dihuanng pill is an effective treatment for chronic kidney disease, but its treatment mechanism is unclear. The rapid development of network pharmacology has provided new strategies for studying Chinese medicine. Method: The traditional Chinese medicine systems pharmacology database and analysis platform was used to obtain the bioactive components and targets of Liuwei Dihuanng pill. The sources for the CKD-related targets were then obtained from the Genecards, OMIM, TTD, and DisGeNET databases. R was used to identify the intersecting genes for Liuwei Dihuang pill and CKD-related targets. Analysis of protein-protein interactions (PPI) was performed using STRING, and PPI networks and drug-component-target networks were constructed using Cytoscape software. Kyoto encyclopedia of genes and genomes pathway and gene ontology enrichment analyses were performed using R. Finally, molecular docking was performed to determine the binding activity between bioactive components and the targets. Result: After screening and data de-duplication of 74 active components, 209 drug targets, and 14,794 disease targets, a total of 204 drug-disease targets were acquired. Subsequently, a drug-component-target network and PPI network were established. The primary components of Liuwei Dihuang pill included quercetin, stigmasterol, kaempferol, beta-sitosterol, tetrahydroalstonine, kadsurenone, hederagenin, hancinone C, diosgenin, and sitosterol. In addition, JUN, AKT1, TP53, RELA, MAPK1, FOS, TNF, IL6, ESR1, and RXRA were identified as the main targets. Gene ontology function enrichment analysis revealed that these targets were involved in reactive oxygen species metabolic processes, responses to metal ions and to chemical stimuli, G protein-coupled amine receptor activity, and nuclear factor receptor activity. Kyoto encyclopedia of genes and genomes enrichment analysis showed that these targets were involved in the AGE-RAGE signaling pathway, IL-17 signaling pathway, TNF signaling pathway, and so on. Molecular docking results indicated good binding activity between the core targets and core components. Conclusion: The potential mechanism of Liuwei Dihuanng pill in the treatment of CKD was preliminarily discussed in this study, providing a theoretical basis and evidence for further experimental research.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference63 articles.

1. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease.;Kidney Int,2020

2. Modulation of oxidative stress in chronic kidney disease patients with different physiopathological conditions.;Meziri;J Complement Med Res,2022

3. Prevention and treatment of stroke in patients with chronic kidney disease: an overview of evidence and current guidelines.;Kelly;Kidney Int,2020

4. Chronic kidney disease and exposure to nephrotoxic metals.;Orr;Int J Mol Sci,2017

5. Estimation of Renin enzyme activity and some biochemical parameters among chronic renal failure patients in Tikrit city.;Hameed;J Popul Ther Clin Pharmacol,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3